Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
GKOS

GKOS - Glaukos Corp Stock Price, Fair Value and News

120.82USD+2.11 (+1.78%)Market Closed

Market Summary

GKOS
USD120.82+2.11
Market Closed
1.78%

GKOS Alerts

  • 1 major insider sales recently.

GKOS Stock Price

View Fullscreen

GKOS RSI Chart

GKOS Valuation

Market Cap

6.1B

Price/Earnings (Trailing)

-43.2

Price/Sales (Trailing)

18.64

EV/EBITDA

-51.68

Price/Free Cashflow

-80.95

GKOS Price/Sales (Trailing)

GKOS Profitability

EBT Margin

-42.88%

Return on Equity

-31.25%

Return on Assets

-15.09%

Free Cashflow Yield

-1.24%

GKOS Fundamentals

GKOS Revenue

Revenue (TTM)

326.4M

Rev. Growth (Yr)

15.86%

Rev. Growth (Qtr)

3.95%

GKOS Earnings

Earnings (TTM)

-140.9M

Earnings Growth (Yr)

-17.94%

Earnings Growth (Qtr)

-11.04%

Breaking Down GKOS Revenue

Last 7 days

-0.2%

Last 30 days

6.6%

Last 90 days

25.2%

Trailing 12 Months

58.7%

How does GKOS drawdown profile look like?

GKOS Financial Health

Current Ratio

5.38

Debt/Equity

0

Debt/Cashflow

-79.56

GKOS Investor Care

Shares Dilution (1Y)

4.48%

Diluted EPS (TTM)

-2.88

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2024326.4M000
2023289.1M296.8M303.6M314.7M
2022293.7M288.3M284.9M282.9M
2021237.6M284.1M294.0M294.0M
2020238.3M211.3M217.6M225.0M
2019195.2M210.6M225.2M237.0M
2018163.5M165.4M168.9M181.3M
2017127.2M139.9M150.8M159.3M
201680.1M90.9M101.5M114.4M
201552.0M58.7M65.5M71.7M
201427.1M33.3M39.4M45.6M
201300020.9M

Tracking the Latest Insider Buys and Sells of Glaukos Corp

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jul 05, 2024
gilliam joseph e
acquired
155,925
69.3
2,250
president & coo
Jul 05, 2024
gilliam joseph e
sold
-273,128
121
-2,250
president & coo
Jun 24, 2024
navratil tomas
sold (taxes)
-48,427
93.13
-520
chief development officer
Jun 24, 2024
burns thomas william
sold (taxes)
-98,531
93.13
-1,058
chairman & ceo
Jun 03, 2024
gilliam joseph e
acquired
137,950
55.18
2,500
president & coo
Jun 03, 2024
gilliam joseph e
sold
-283,751
113
-2,500
president & coo
May 30, 2024
kliman gilbert h
acquired
160,000
32.00
5,000
-
May 30, 2024
kliman gilbert h
sold
-560,000
112
-5,000
-
May 30, 2024
hoffmeister david f
acquired
-
-
1,716
-
May 30, 2024
foley mark j
acquired
-
-
1,716
-

1–10 of 50

Which funds bought or sold GKOS recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jul 19, 2024
Continuum Advisory, LLC
unchanged
-
108
1,184
-%
Jul 19, 2024
NISA INVESTMENT ADVISORS, LLC
added
1.92
56,149
257,175
-%
Jul 19, 2024
RAYMOND JAMES & ASSOCIATES
added
23.21
544,388
1,540,560
-%
Jul 19, 2024
First Horizon Advisors, Inc.
unchanged
-
8,397
41,304
-%
Jul 18, 2024
Assenagon Asset Management S.A.
new
-
6,832,460
6,832,460
0.01%
Jul 18, 2024
Blue Trust, Inc.
new
-
4,243
4,243
-%
Jul 17, 2024
SWS Partners
new
-
9,586
9,586
-%
Jul 17, 2024
Yarbrough Capital, LLC
unchanged
-
113,756
559,559
0.02%
Jul 17, 2024
KBC Group NV
added
19.5
49,000
147,000
-%
Jul 17, 2024
RIVERBRIDGE PARTNERS LLC
reduced
-7.75
7,956,140
58,355,400
0.79%

1–10 of 43

Are Funds Buying or Selling GKOS?

Are funds buying GKOS calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own GKOS
No. of Funds

Unveiling Glaukos Corp's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
brown capital management llc
5.53%
2,697,794
SC 13G/A
Feb 13, 2024
burns thomas william
5.08%
2,552,501
SC 13G/A
Feb 13, 2024
vanguard group inc
10.73%
5,236,738
SC 13G/A
Feb 09, 2024
fmr llc
-
0
SC 13G/A
Jan 22, 2024
blackrock inc.
16.2%
7,894,315
SC 13G/A
Jan 10, 2024
wellington management group llp
2.75%
1,340,500
SC 13G/A
Dec 11, 2023
fmr llc
-
0
SC 13G
Feb 14, 2023
burns thomas william
5.71%
2,807,641
SC 13G/A
Feb 14, 2023
brown capital management llc
5.69%
2,712,809
SC 13G/A
Feb 09, 2023
vanguard group inc
11.21%
5,349,225
SC 13G/A

Recent SEC filings of Glaukos Corp

View All Filings
Date Filed Form Type Document
Jul 09, 2024
4
Insider Trading
Jul 05, 2024
144
Notice of Insider Sale Intent
Jun 28, 2024
8-K
Current Report
Jun 26, 2024
4
Insider Trading
Jun 26, 2024
4
Insider Trading
Jun 14, 2024
8-K
Current Report
Jun 05, 2024
4
Insider Trading
Jun 05, 2024
8-K
Current Report
Jun 03, 2024
4
Insider Trading
Jun 03, 2024
4
Insider Trading

Peers (Alternatives to Glaukos Corp)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
177.6B
40.3B
-1.87% -8.75%
31.54
4.4
-2.84% -3.00%
66.7B
19.7B
-1.27% -12.39%
50.03
3.38
4.82% -17.56%
18.9B
3.9B
3.77% -24.06%
40.93
4.83
5.72% 46.72%
18.0B
14.9B
4.77% -28.30%
6.8
1.21
2.98% 207.68%
MID-CAP
9.7B
3.5B
-0.49% 22.32%
30.92
2.73
6.16% 35.06%
9.0B
12.4B
3.05% -11.95%
23.22
0.73
-0.93% -18.83%
8.5B
2.6B
2.70% -25.47%
-26.25
3.25
-6.25% -68.58%
5.5B
3.9B
2.69% -35.08%
-57.29
1.39
0.23% 90.80%
3.5B
387.1M
0.41% 33.97%
-217.07
8.93
30.82% 65.57%
2.2B
6.6B
-1.26% -22.56%
11.83
0.33
1.50% -10.09%
SMALL-CAP
1.4B
3.2B
-5.25% -24.25%
-2.04
0.44
7.94% -1695.32%
408.8M
169.3M
6.32% 8.33%
-5.32
2.42
7.49% -244.90%
287.6M
324.0M
27.08% -17.85%
-1.5
0.89
-3.19% -337.41%
46.8M
50.5M
-0.74% -76.96%
-2.05
0.93
14.25% -10.06%
5.7M
3.5M
-39.71% -89.21%
-0.47
1.62
-0.62% -1.48%

Glaukos Corp News

Latest updates
MarketBeat18 Jul 202408:57 pm
American Banking and Market News18 Jul 202405:40 am
Seeking Alpha10 Jul 202407:00 am
Yahoo Finance03 Jul 202407:00 am
Yahoo Finance27 Jun 202407:00 am

Glaukos Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue4.0%85,622,00082,365,00078,048,00080,399,00073,899,00071,227,00071,269,00072,685,00067,681,00073,240,00074,710,00078,093,00067,968,00073,234,00064,831,00031,558,00055,336,00065,849,00058,509,00058,600,00054,026,000
Gross Profit3.0%65,364,00063,474,00059,538,00060,296,00055,828,00054,005,00054,408,00054,852,00050,618,00056,375,00059,340,00060,334,00051,335,00053,644,00046,899,0009,890,00022,807,00049,945,00050,806,00050,730,00046,915,000
Operating Expenses2.3%104,430,000102,096,00087,548,00089,371,00088,821,00087,739,00076,019,00091,612,00040,826,00074,244,00048,316,00074,556,00063,140,00065,036,00059,251,00057,087,00075,419,00079,642,00063,221,00056,970,00048,855,000
  S&GA Expenses-1.7%61,975,00063,034,00054,247,00053,137,00053,650,00051,927,00047,149,00049,900,00043,949,00047,566,00044,470,00045,300,00041,921,00043,792,00038,947,00038,116,00050,546,00059,611,00044,443,00037,656,00034,925,000
  R&D Expenses---------26,877,000---21,219,000-------13,930,000
EBITDA Margin-1.2%-0.36-0.35-0.35-0.35-0.41-0.28-0.24-0.13-0.03-0.11-0.08-0.16-0.32--------
Interest Expenses0.6%3,450,0003,428,0003,398,0003,399,0003,408,0003,409,0003,481,0003,414,0003,416,0003,424,0003,413,0003,306,0003,229,000--------
Income Taxes380.3%377,00078,50037,000400,000401,000298,000247,000-105,000300,000-363,000202,000208,000279,000-3,243,000-889,000-7,384,000-450,000-65,841,000187,00072,000122,000
Earnings Before Taxes-10.2%-40,461,000-36,718,000-30,407,000-32,377,000-34,225,000-31,162,000-27,329,000-45,641,0005,703,000-22,235,0006,432,000-17,274,000-16,190,000-13,891,000-16,637,000-47,278,000-54,508,000-29,260,000-13,319,000-6,237,000-1,220,000
EBT Margin-0.9%-0.43-0.42-0.42-0.42-0.48-0.35-0.31-0.19-0.09-0.17-0.14-0.23-0.40--------
Net Income-11.0%-40,838,000-36,779,000-30,444,000-32,812,000-34,626,000-31,460,000-27,576,000-45,536,0005,377,000-21,872,0006,230,000-17,482,000-16,469,000-10,648,000-15,748,000-39,894,000-54,058,00036,581,000-13,506,000-6,309,000-1,342,000
Net Income Margin-0.9%-0.43-0.43-0.43-0.43-0.48-0.35-0.31-0.19-0.09-0.17-0.13-0.21-0.35--------
Free Cashflow-134.1%-34,838,000-14,879,000-11,528,000-13,927,000-37,672,000-12,357,000-32,554,000-21,607,0003,170,000-13,978,0007,874,000-3,969,000-13,004,000--------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-0.8%9339409499579731,0021,0081,0311,0521,0501,0641,0441,0231,006995996780818307302228
  Current Assets-1.7%389395400401416444449471491486502491474469454453231263209201184
    Cash Equivalents-54.5%42.0093.0010995.0083.0012711311211610112312810610690.0027663.0072.0048.0049.0042.00
  Inventory19.5%50.0042.0040.0039.0040.0038.0034.0028.0025.0023.0020.0018.0015.0016.0020.0021.0028.0043.0013.0014.0013.00
  Net PPE-1.3%10210310310398.0094.0087.0081.0075.0069.0061.0054.0043.0024.0023.0023.0023.0022.0020.0020.0020.00
  Goodwill0%66.0066.0066.0066.0066.0066.0066.0066.0066.0066.0066.0066.0066.0066.0066.0066.0066.0066.00---
Liabilities0.8%48347947146846447246046945546346345943333833333313814511711443.00
  Current Liabilities-2.4%72.0074.0067.0064.0062.0072.0061.0070.0056.0063.0063.0034933650.0047.0055.0051.0058.0033.0031.0027.00
    LT Debt, Current------------279279--------
Shareholder's Equity-2.4%451462478489509530549562598587601584590667662662641673190188185
  Retained Earnings-6.8%-639-599-562-531-499-464-432-405-359-365-343-349-332-310-299-283-243-189-226-212-206
  Additional Paid-In Capital2.8%1,0891,0601,0391,0211,009997985972961952943933921977959944883862415399391
Shares Outstanding1.5%50.0049.0049.0048.0048.0048.0047.0047.0047.0046.0047.0046.00---------
Float----3,445---2,067---3,792---1,634---2,679-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-217.6%-33,870-10,665-8,168-8,161-30,764-4,136-26,515-12,2069,774-4,65117,7907,3914,17810,604-9,570-10,923-13,099-4,191-2,9886,602208
  Share Based Compensation-14.0%11,16512,98710,4849,87310,18411,6889,41110,5396,9237,2256,1897,9848,7488,7449,66010,89717,17612,4708,5478,2477,129
Cashflow From Investing-127.4%-29,383-12,92114,89725,951-13,83216,65524,3919,630-5,897-8,872-26,063-2,034-21,263-3,459-181,562-20,66762849,812-4,074-599-1,713
Cashflow From Financing80.3%13,1677,3037,467-8801,1525294,2061061,4101,6173,86716,36217,4148,6595,821243,8424,220-22,0366,6663185,407
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

GKOS Income Statement

2024-03-31
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS  
Net sales$ 85,622$ 73,899
Cost of sales20,25818,071
Gross profit65,36455,828
Operating expenses:  
Selling, general and administrative61,97553,650
Research and development30,72635,171
Acquired in-process research and development11,729 
Total operating expenses104,43088,821
Loss from operations(39,066)(32,993)
Non-operating expense:  
Interest income3,0831,648
Interest expense(3,450)(3,408)
Other (expense) income, net(1,028)528
Total non-operating expense(1,395)(1,232)
Loss before taxes(40,461)(34,225)
Income tax provision377401
Net loss$ (40,838)$ (34,626)
Basic net loss per share (in dollar per share)$ (0.82)$ (0.72)
Diluted net loss per share (in dollar per share)$ (0.82)$ (0.72)
Weighted average shares outstanding used to compute basic net loss per share49,58047,881
Weighted average shares outstanding used to compute diluted net loss per share49,58047,881

GKOS Balance Sheet

2024-03-31
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 42,495$ 93,467
Short-term investments230,365201,964
Accounts receivable, net46,54539,850
Inventory50,18541,986
Prepaid expenses and other current assets19,02018,194
Total current assets388,610395,461
Restricted cash5,8565,856
Property and equipment, net101,858103,212
Operating lease right-of-use assets26,68327,146
Finance lease right-of-use asset43,57544,180
Intangible assets, net281,919282,956
Goodwill66,13466,134
Deposits and other assets18,70315,469
Total assets933,338940,414
Current liabilities:  
Accounts payable12,75213,440
Accrued liabilities59,48660,574
Total current liabilities72,23874,014
Convertible senior notes283,117282,773
Operating lease liability30,11030,427
Finance lease liability70,28970,538
Deferred tax liability, net7,1447,144
Other liabilities19,71013,752
Total liabilities482,608478,648
Commitments and contingencies (Note 12)
Stockholders' equity:  
Preferred stock, $0.001 par value; 5,000 shares authorized; no shares issued or outstanding
Common stock, $0.001 par value; 150,000 shares authorized; 49,875 and 49,148 shares issued and 49,847 and 49,120 shares outstanding as of March 31, 2024 and December 31, 2023, respectively5049
Additional paid-in capital1,089,2801,059,751
Accumulated other comprehensive income1,4371,165
Accumulated deficit(639,905)(599,067)
Less treasury stock (28 shares as of March 31, 2024 and December 31, 2023)(132)(132)
Total stockholders' equity450,730461,766
Total liabilities and stockholders' equity$ 933,338$ 940,414
GKOS
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, an implantable device intended to reduce the intraocular pressure of the eye; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo California.
 CEO
 WEBSITEglaukos.com
 INDUSTRYMedical Instruments & Supplies
 EMPLOYEES783

Glaukos Corp Frequently Asked Questions


What is the ticker symbol for Glaukos Corp? What does GKOS stand for in stocks?

GKOS is the stock ticker symbol of Glaukos Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Glaukos Corp (GKOS)?

As of Fri Jul 19 2024, market cap of Glaukos Corp is 6.09 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of GKOS stock?

You can check GKOS's fair value in chart for subscribers.

What is the fair value of GKOS stock?

You can check GKOS's fair value in chart for subscribers. The fair value of Glaukos Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Glaukos Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for GKOS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Glaukos Corp a good stock to buy?

The fair value guage provides a quick view whether GKOS is over valued or under valued. Whether Glaukos Corp is cheap or expensive depends on the assumptions which impact Glaukos Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for GKOS.

What is Glaukos Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jul 19 2024, GKOS's PE ratio (Price to Earnings) is -43.2 and Price to Sales (PS) ratio is 18.64. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. GKOS PE ratio will change depending on the future growth rate expectations of investors.